{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:24:41Z","timestamp":1793834681442,"version":"4.6.1"},"reference-count":19,"publisher":"American Society of Hematology","issue":"19","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10,14]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Bispecific antibodies for treatment for multiple myeloma are highly effective but commonly cause cytokine release syndrome (CRS) and immune effector cell\u2013associated neurotoxicity syndrome (ICANS). Emerging data indicate that prophylactic tocilizumab may reduce CRS, without impacting efficacy. We administered a single dose of tocilizumab before the first dose of bispecific antibodies to 119 patients to determine the impact on CRS in a real-world setting including B-cell maturation antigen \u00d7 CD3\u2013 and G-protein\u2013coupled receptor class C group 5 member D \u00d7 CD3\u2013targeted antibodies. The best overall response rate was 65.7% (binomial 95% confidence interval [CI], 55.8-74.7). We observed a low overall rate of CRS (10.1%; 95% CI, 5.3-17). For teclistamab, elranatamab, linvoseltamab, and talquetamab individually, the CRS rate was 8.9%, 12.5%, 0%, and 13%, respectively. The overall rate of ICANS (5.9%; 95% CI, 2.4-11.7) was low but similar to rates without prophylactic tocilizumab. CRS was limited to grade 1 for 10 of 12 events. There were no grade 3 CRS events, and no additional doses of tocilizumab or corticosteroids were given for CRS. Our real-world evidence results suggest that tocilizumab may be effective as a preventive, rather than reactive, measure to prevent CRS without compromising efficacy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025016911","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T10:50:53Z","timestamp":1751367053000},"page":"4979-4986","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":37,"title":["Tocilizumab prophylaxis for patients with multiple myeloma treated with bispecific antibodies"],"prefix":"10.1182","volume":"9","author":[{"given":"Andrew","family":"Kowalski","sequence":"first","affiliation":[{"name":"Myeloma Division, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2298-7829","authenticated-orcid":false,"given":"Jill","family":"Lykon","sequence":"additional","affiliation":[{"name":"Myeloma Division, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8638-9365","authenticated-orcid":false,"given":"Benjamin","family":"Diamond","sequence":"additional","affiliation":[{"name":"Myeloma Division, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3544-8836","authenticated-orcid":false,"given":"David","family":"Coffey","sequence":"additional","affiliation":[{"name":"Myeloma Division, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcella","family":"Kaddoura","sequence":"additional","affiliation":[{"name":"Myeloma Division, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Maura","sequence":"additional","affiliation":[{"name":"Myeloma Division, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Hoffman","sequence":"additional","affiliation":[{"name":"Myeloma Division, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7766-5831","authenticated-orcid":false,"given":"Abhishek","family":"Pandey","sequence":"additional","affiliation":[{"name":"Myeloma Division, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dickran","family":"Kazandjian","sequence":"additional","affiliation":[{"name":"Myeloma Division, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6485-4839","authenticated-orcid":false,"given":"Ola","family":"Landgren","sequence":"additional","affiliation":[{"name":"Myeloma Division, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"issue":"13","key":"2025101410314896200_bib1","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1080\/10428194.2022.2113532","article-title":"T cell redirecting bispecific antibodies for multiple myeloma: emerging therapeutic strategies in a changing treatment landscape","volume":"63","author":"Kazandjian","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"2025101410314896200_bib2","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1016\/S1470-2045(24)00043-3","article-title":"International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma","volume":"25","author":"Rodriguez-Otero","year":"2024","journal-title":"Lancet Oncol"},{"issue":"2","key":"2025101410314896200_bib3","doi-asserted-by":"crossref","first-page":"108.e1","DOI":"10.1016\/j.jtct.2022.11.004","article-title":"Epidemiology and predictors of 30-day readmission in CAR-T cell therapy recipients","volume":"29","author":"Sharma","year":"2023","journal-title":"Transpl Cell Ther"},{"issue":"1","key":"2025101410314896200_bib4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11899-024-00748-5","article-title":"Navigating the economic burden of multiple myeloma: insights into cost-effectiveness of CAR-T and bispecific antibody therapies","volume":"20","author":"Keesari","year":"2025","journal-title":"Curr Hematol Malig Rep"},{"key":"2025101410314896200_bib5","author":"Niels WCJ van de Donk","year":"31   4  2024"},{"issue":"suppl 1","key":"2025101410314896200_bib6","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1182\/blood-2022-159381","article-title":"Pretreatment with tocilizumab before the CD3 bispecific cevostamab in patients with relapsed\/refractory multiple myeloma (RRMM) showed a marked reduction in cytokine release syndrome incidence and severity","volume":"140","author":"Trudel","year":"2022","journal-title":"Blood"},{"issue":"2","key":"2025101410314896200_bib7","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1158\/2643-3230.BCD-23-0228","article-title":"Emerging strategies for the prevention of immune toxicities associated with T cell-engaging cancer therapies","volume":"5","author":"Kowalski","year":"2024","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"2025101410314896200_bib8","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/s41408-023-00963-y","article-title":"Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: a single-center experience","volume":"13","author":"Scott","year":"2023","journal-title":"Blood Cancer J"},{"issue":"7","key":"2025101410314896200_bib9","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1002\/hem3.132","article-title":"Prophylactic tocilizumab reduces the incidence of cytokine release syndrome in relapsed\/refractory myeloma patients treated with teclistamab: implications for outpatient step-up dosing","volume":"8","author":"Korst","year":"2024","journal-title":"Hemasphere"},{"issue":"suppl 1","key":"2025101410314896200_bib10","doi-asserted-by":"crossref","first-page":"4720","DOI":"10.1182\/blood-2024-204361","article-title":"Prophylactic dexamethasone and remote monitoring for patients with relapsed refractory multiple myeloma (RRMM) receiving bispecific antibodies (BsAb): experience at a single institution","volume":"144","author":"Varga","year":"2024","journal-title":"Blood"},{"issue":"suppl 1","key":"2025101410314896200_bib11","doi-asserted-by":"crossref","first-page":"4753","DOI":"10.1182\/blood-2024-207295","article-title":"Optec: a phase 2 study to evaluate outpatient step-up administration of teclistamab in patients with relapsed\/refractory multiple myeloma (RRMM): updated results","volume":"144","author":"Rifkin","year":"2024","journal-title":"Blood"},{"issue":"4","key":"2025101410314896200_bib12","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"2025101410314896200_bib13","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa2406536","article-title":"Talquetamab plus teclistamab in relapsed or refractory multiple myeloma","volume":"392","author":"Cohen","year":"2025","journal-title":"N Engl J Med"},{"issue":"1","key":"2025101410314896200_bib14","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41408-024-01003-z","article-title":"Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study","volume":"14","author":"Mohan","year":"2024","journal-title":"Blood Cancer J"},{"issue":"6","key":"2025101410314896200_bib15","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"issue":"9","key":"2025101410314896200_bib16","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"issue":"24","key":"2025101410314896200_bib17","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell\u2013redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"issue":"22","key":"2025101410314896200_bib18","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1200\/JCO.24.01008","article-title":"Linvoseltamab for treatment of relapsed\/refractory multiple myeloma","volume":"42","author":"Bumma","year":"2024","journal-title":"J Clin Oncol"},{"issue":"5","key":"2025101410314896200_bib19","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1200\/OP-24-00489","article-title":"Real-world safety and health care resource utilization of teclistamab under an outpatient model for step-up dosing administration","volume":"21","author":"Sandahl","year":"2025","journal-title":"JCO Oncol Pract"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/19\/4979\/2414884\/blooda_adv-2025-016911-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/19\/4979\/2414884\/blooda_adv-2025-016911-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T14:41:18Z","timestamp":1760452878000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/19\/4979\/538036\/Tocilizumab-prophylaxis-for-patients-with-multiple"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":19,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2025,10,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025016911","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10,14]]},"published":{"date-parts":[[2025,9,30]]}}}